Broad Pharma to participate in Belgian company to introduce mRNA vaccine technology

On June 1, BroadPharma announced that the Group had recently entered into an equity investment agreement with eTheA Immunres NV (eTheRNA) in Belgium, which will invest 9 million euros in eTheRNA after the terms agreed in the investment agreement have been metAccording to the announcement, eTheRNA is a clinical-phasemed mRNA (ribonucleic acid) new vaccine technology company, founded in 2013 by professor Kris Thielemans, a renowned immunologist at the Free University of Brussels, in conjunction with other partners, and has been granted a global exclusive license for VUB's TriMix-related technologyUpon completion of the transaction, Broad Pharma will receive approximately 13% of eTheRNA's Class B preferred shares and a board seatUnder the terms of the strategic cooperation, the partnership includes the introduction of eTheRNA mRNA production technology, independent research and development, production and commercialization activities in related fields, and the acquisition of eTheRNA's exclusive right to develop and commercialize in ChinamRNA technology is a new generation of vaccine technology that has emerged in recent years, producing nucleic acids (drugs/vaccines) with genetic code without the need for actual samples of viruses or their proteins, instructing the body's own cells to synthesize certain proteins from the virus to trigger an immune responseHowever, so far, the field of mRNA vaccine therapy in the global scope is in the early stage of research and development, the world's fastest-growing companies are mainly in the clinical phase I and II research stage, has not yet formed a clear leading enterprise advantageSource: Great Pharmaceutical Bulletin